RVNC Revance Therapeutics, Inc.

21.95
+0.70  (3%)
Previous Close 21.25
Open 21.15
Price To book 3.58
Market Cap 664.49M
Shares 30,273,000
Volume 361,277
Short Ratio 19.71
Av. Daily Volume 187,855

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 17866406
  2. CT ORDER - Confidential treatment order 17862965
  3. CT ORDER - Confidential treatment order 17859552
  4. 8-K - Current report 17855163
  5. 8-K - Current report 17839376

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RT002 - SAKURA 2
Moderate to severe glabellar (frown) lines
Phase 2 data due 4Q 2017.
RT002
Plantar fasciitis
Phase 3 endpoints not met June 2016
RT001 - REALISE 1
Lateral Canthal (Crow’s Feet) Lines
Phase 2 additional data released May 18, 2017 with oral presentation June 8, 2017 at International Congress of Parkinson's Disease and Movement Disorders.
RT002
Cervical dystonia
Phase 3 completion of enrollment announced March 8, 2017. Data due 4Q 2017.
RT002 - SAKURA 1
Moderate to severe glabellar (frown) lines

Latest News

  1. Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : May 26, 2017
  2. Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial
  3. Edited Transcript of RVNC earnings conference call or presentation 9-May-17 8:30pm GMT
  4. ETFs with exposure to Revance Therapeutics, Inc. : May 15, 2017
  5. Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : May 15, 2017
  6. Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  7. Revance reports 1Q loss
  8. Revance Releases First Quarter 2017 Results
  9. Investor Network: Revance Therapeutics, Inc. to Host Earnings Call
  10. Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis
  11. Revance Therapeutics to Release First Quarter 2017 Financial Results Tuesday, May 9, 2017
  12. Revance Therapeutics, Inc. – Value Analysis (NASDAQ:RVNC) : April 20, 2017
  13. Revance Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : RVNC-US : April 19, 2017
  14. Revance Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : RVNC-US : March 21, 2017
  15. Revance Therapeutics, Inc. :RVNC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  16. Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines
  17. Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting
  18. Edited Transcript of RVNC earnings conference call or presentation 27-Feb-17 9:30pm GMT

SEC Filings

  1. CT ORDER - Confidential treatment order 17866406
  2. CT ORDER - Confidential treatment order 17862965
  3. CT ORDER - Confidential treatment order 17859552
  4. 8-K - Current report 17855163
  5. 8-K - Current report 17839376
  6. 8-K - Current report 17827633
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 17827470
  8. 8-K - Current report 17826535
  9. DEF 14A - Other definitive proxy statements 17713347
  10. 8-K - Current report 17689449